Brain Hemorrhage - Pipeline Review, H2 2016

  • ID: 3984501
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Edge Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fina Biotech
  • MediPost Co Ltd
  • Pfizer Inc
  • MORE
Brain Hemorrhage - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides an overview of the Brain Hemorrhage (Central Nervous System) pipeline landscape.

Brain hemorrhage is a type of stroke. It is caused by the bursting of an artery in the brain that leads to localized bleeding in the surrounding tissues. This bleeding kills the brain cells. The common risk factors of brain haemorrhages include head trauma, high blood pressure, aneurysm, blood vessel abnormalities, amyloid angiopathy, blood or bleeding disorders such as hemophilia and sickle cell anemia, liver disease and brain tumors. Symptoms include sudden severe headache, seizures, weakness in an arm or leg, nausea or vomiting, lethargy, changes in vision, tingling or numbness, difficulty in speaking or understanding speech, difficulty in swallowing, difficulty in writing or reading, loss of fine motor skills such as hand tremors, loss of coordination, loss of balance, abnormal sense of taste and loss of consciousness.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Hemorrhage (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Hemorrhage (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively.Brain Hemorrhage.

Brain Hemorrhage (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Hemorrhage (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Hemorrhage (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Hemorrhage (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Hemorrhage (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Hemorrhage (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Hemorrhage (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Hemorrhage (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Edge Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fina Biotech
  • MediPost Co Ltd
  • Pfizer Inc
  • MORE
List of Tables

List of Figures

Introduction

Brain Hemorrhage Overview

Therapeutics Development

Pipeline Products for Brain Hemorrhage - Overview

Brain Hemorrhage - Therapeutics under Development by Companies

Brain Hemorrhage - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Brain Hemorrhage - Products under Development by Companies

Brain Hemorrhage - Companies Involved in Therapeutics Development

Bio Products Laboratory Ltd

Edge Therapeutics Inc

F. Hoffmann-La Roche Ltd

Fina Biotech

MediPost Co Ltd

Pfizer Inc

Remedy Pharmaceuticals Inc

Brain Hemorrhage - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

alteplase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprotinin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CN-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glyburide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

haptoglobin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05230907 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pneumostem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRC-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit tPA and uPA for Intracranial Hemorrhage - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMP-HPE - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Brain Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brain Hemorrhage - Dormant Projects

Brain Hemorrhage - Discontinued Products

Brain Hemorrhage - Product Development Milestones

Featured News & Press Releases

Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Hemorrhage, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Brain Hemorrhage - Pipeline by Bio Products Laboratory Ltd, H2 2016

Brain Hemorrhage - Pipeline by Edge Therapeutics Inc, H2 2016

Brain Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016

Brain Hemorrhage - Pipeline by Fina Biotech, H2 2016

Brain Hemorrhage - Pipeline by MediPost Co Ltd, H2 2016

Brain Hemorrhage - Pipeline by Pfizer Inc, H2 2016

Brain Hemorrhage - Pipeline by Remedy Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Brain Hemorrhage - Dormant Projects, H2 2016

Brain Hemorrhage - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Brain Hemorrhage, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bio Products Laboratory Ltd
  • Edge Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fina Biotech
  • MediPost Co Ltd
  • Pfizer Inc
  • Remedy Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll